Bioresorbable vascular scaffold for the treatment of coronary in-stent restenosis: New dawn or frost on snow?
BVS might be non-inferiority compared to DES or DEB in ISR treatment in terms of 1-year DOCE. BVS, especially thinner-strut stent may be an attractive alternative in ISR setting. Large prospective randomized trials are needed to provide convince evidences to direct clinical practice in the future.